Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
An update from Rapid Micro Biosystems ( (RPID) ) is now available.
On January 16, 2025, Rapid Micro Biosystems updated its corporate presentation for investor meetings, highlighting their record revenue growth in 2024 and strategic collaboration with Lonza. The company reported strong year-over-year growth of approximately 25% and exceeded its revenue guidance for the year, with a notable increase in system placements and global validations, reinforcing its position in the pharmaceutical manufacturing process.
More about Rapid Micro Biosystems
Rapid Micro Biosystems specializes in automated microbial quality control testing for the pharmaceutical industry. Their key offering, the Growth Direct platform, integrates cutting-edge technology to streamline and modernize the testing process, enhancing data integrity, operational efficiency, and regulatory compliance.
YTD Price Performance: 29.08%
Average Trading Volume: 97,563
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $46.91M
For detailed information about RPID stock, go to TipRanks’ Stock Analysis page.
